Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting

Yang Yang1, YanFang Yang1, XiangYang Xie2

  • 1Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.

Biomaterials
|February 22, 2015
PubMed

Insights

This study introduces a novel nanocarrier for targeted siRNA delivery using near-infrared light activation. The system enhances tumor cell uptake and gene silencing, offering a promising approach for cancer therapy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Drug Delivery

Background:

  • Photosensitive nanocarriers face limitations in vivo due to UV light's poor tissue penetration and toxicity.
  • Near-infrared (NIR) light offers deeper tissue penetration and reduced cellular damage compared to UV light for triggered drug release.

Purpose of the Study:

  • To develop and evaluate a functional siRNA delivery system using cationic liposomes modified with a photolabile-caged cell-penetrating peptide (pcCPP) and NGR peptide.
  • To achieve NIR light-dependent, tumor-targeted siRNA delivery and enhanced cellular uptake.

Main Methods:

  • siRNA was loaded into cationic liposomes functionalized with pcCPP and NGR peptides (pcCPP/NGR-LP).
  • The pcCPP's cell-penetrating ability was masked by a photosensitive group, activated by NIR light.
  • NGR moiety targeted CD13-positive tumors, facilitating accumulation and selective uptake upon NIR irradiation.

Main Results:

  • pcCPP/NGR-LP demonstrated favorable physicochemical properties, efficient cellular uptake, and endosomal escape in vitro.
  • NIR light activation of pcCPP/NGR-LP led to enhanced tumor cell penetration and gene silencing (c-myc) in vitro and in vivo.
  • Systemic administration in mice resulted in tumor accumulation, c-myc silencing, and delayed tumor progression.

Conclusions:

  • The pcCPP/NGR-LP system enables selective, NIR light-triggered siRNA delivery to tumors.
  • This dual-modified nanocarrier approach shows potential for targeted gene silencing in cancer therapy.